Contextlogic Inc. - LOGC STOCK NEWS

LogicBio Therapeutics (Nasdaq: LOGC) announced its intention to conduct an underwritten public offering of common stock. The offering includes a 30-day option for underwriters to purchase an additional 15% of shares. The company plans to use net proceeds to support clinical development of LB-001, advance GeneRide and Next Generation Capsid platforms, and expand its product pipeline. The offering is subject to market conditions and conducted under an effective shelf registration statement. No assurance is provided on the completion or terms of the offering.

LogicBio Therapeutics, Inc. (Nasdaq: LOGC) announced that CEO Fred Chereau will present at the Jefferies Virtual Gene Editing/Therapy Summit on October 2, 2020, at 11:30 AM ET. The presentation will be available via a live audio webcast on LogicBio’s website, with a replay accessible one hour post-event for 30 days. The company specializes in genome editing to treat rare pediatric diseases, utilizing its GeneRide platform for site-specific therapeutic transgene integration, aiming to meet significant medical needs.

LogicBio Therapeutics (Nasdaq: LOGC) announced that CEO Fred Chereau will present at the Chardan Virtual Genetic Medicines Conference on October 5, 2020, at 11 AM ET. The presentation will be available via live audio webcast on LogicBio's website, with a replay accessible one hour after the event for 30 days. LogicBio focuses on developing medicines for rare diseases in pediatric patients using its GeneRide™ technology platform, which enables site-specific integration of therapeutic transgenes without nucleases, aiming for lifelong expression.

LogicBio Therapeutics has received FDA clearance for its first investigational new drug application (IND) to initiate a Phase 1/2 clinical trial for LB-001, a treatment for methylmalonic acidemia (MMA). The SUNRISE trial will enroll pediatric patients aged 3 months to 12 years, focusing on safety and tolerability of LB-001. Initial dosing will start with patients aged 3-12 years, moving to younger cohorts as safety is established. The first patient enrollment is expected in early 2021, marking a significant milestone for the company and the genetic medicine sector.

LogicBio Therapeutics (Nasdaq:LOGC) reported its financial results for Q2 2020, showing a net loss of $8.2 million, or $0.35 per share, an improvement from $10 million, or $0.45 per share in Q2 2019. R&D expenses decreased to $5.9 million, primarily due to lower external development costs for LB-001, while G&A expenses rose to $3.0 million. The FDA has cleared the IND for LB-001 for treating methylmalonic acidemia, a significant milestone. The company expects to enroll the first patient in early 2021 and has a cash position of $36.7 million, expected to sustain operations into Q3 2021.

LogicBio Therapeutics (Nasdaq: LOGC) announced its 2020 Annual Meeting of Stockholders will proceed in a virtual-only format on June 19, 2020, at 9:00 a.m. E.T. This decision addresses ongoing public health concerns due to COVID-19. Stockholders can participate by registering in advance, with details available on the meeting’s website. Voting in advance is encouraged, and proxy materials are accessible. LogicBio remains committed to developing treatments for rare pediatric diseases using its proprietary GeneRide™ technology.

LogicBio Therapeutics (Nasdaq: LOGC) announced its participation in the Jefferies Virtual Healthcare Conference on June 2, 2020, at 8:00 a.m. ET. The event will feature a live audio webcast available on the company's website, with a replay accessible shortly after the presentation for 30 days.

LogicBio focuses on genome editing to develop medicines for rare pediatric diseases using its GeneRide technology, which enables precise integration of therapeutic transgenes for potentially lifelong expression. More information can be found at www.logicbio.com.

LogicBio Therapeutics (Nasdaq: LOGC) announced its participation in the ASGCT 2020 Annual Meeting, occurring virtually from May 12-15, 2020. The company will present significant data on its GeneRide™ platform, specifically targeting rare diseases in pediatric patients. Highlights include an oral presentation on a methylmalonic acidemia model by Leah Venturoni, alongside multiple poster presentations addressing liver injury, AAV vector development, and gene integration methods. The event reflects LogicBio's commitment to advancing genome editing technologies for effective treatments.

LogicBio Therapeutics (Nasdaq:LOGC) reported its Q1 2020 financial results, highlighting a net loss of $9.5 million, or $0.41 per share, compared to $7.7 million, or $0.34 per share in Q1 2019. R&D expenses rose to $7.2 million, attributed to increased costs for LB-001 and personnel expansion. The firm is advancing LB-001 for methylmalonic acidemia and is in discussions with the FDA for its IND submission. With $43.2 million in cash, LogicBio expects to fund operations through Q2 2021, despite ongoing challenges posed by the COVID-19 pandemic.